This Article Full Text Full Text (PDF) Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Blayney, D. W. Search for Related Content PubMed Articles by Blayney, D. W.

Because this article has no abstract, we have provided an extract of the first 100 words of the full text.

Douglas W. Blayney, MD

Perhaps the greatest challenge currently facing oncologists in the practice setting is the decision whether to participate in the Competitive Acquisition Program (CAP) to acquire drugs for treatment of Medicare-eligible patients. In this issue of the Journal of Oncology Practice, we use a question-and-answer format to focus on CAP. Although CMS has delayed implementation of CAP until July 1, 2006, oncologists will have to elect whether to participate in the program. Participation is a business decision that will depend on individual circumstances. A careful analysis of our article, the primary source document (available at http://www.cms.hhs.gov/providers/drugs/compbid/. . . [Click for More]